Skip to main content

Table 1 Clinical characteristics of the patients in immunohistochemistry analyses

From: Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease

 

Non-smokers

Smokers

COPD st I–II

COPD st IV

p-value

Total (n)

9

10

10

16

 

Male/Female

2/7

9/1

7/3

10/6

 

Age (years)

66 (13)

62 (7)

60 (8)

54 (7)

 

Pack years

0

51 (11)

32 (18)

29 (17)

p < 0.0001

FEV1 (l)

2.7 (1.4)

3.0 (0.8)

2.4 (0.8)

0.6 (0.3)

p < 0.0001

FEV1 (% of ref)

104 (16)

85 (10)

73 (13)

20 (10)

p < 0.0001

FEV1/FVC (%)

85 (10)

79 (7)

70 (12)

34 (9)

p < 0.0001

DCO (% of ref)

91 (18)

79 (15)

69 (13)

25 (8)

p < 0.0001

DCO/VA (% of ref)

90 (12)

83 (12)

71 (14)

37 (10)

p < 0.0001

  1. Data is shown as mean (SD), as % of reference where applicable. None of the patients with stage I–II disease were on oral or inhaled corticosteroids. All patients with stage IV COPD had inhaled corticosteroid (below 1 mg). None of the patients were on N-acetylcysteine or vitamins. No one had previous asbestos exposure.